These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

813 related articles for article (PubMed ID: 30145781)

  • 21. Oncolytic Viruses in Cancer Treatment: A Review.
    Lawler SE; Speranza MC; Cho CF; Chiocca EA
    JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
    Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
    Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safe and Effective Standards of Care: Supporting the Administration of T-VEC for Patients With Advanced Melanoma in the Outpatient Oncology Setting
.
    Wall LM; Baldwin-Medsker A
    Clin J Oncol Nurs; 2017 Oct; 21(5):E260-E266. PubMed ID: 28945708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.
    Burke EE; Zager JS
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):469-473. PubMed ID: 29557682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncolytic Viruses for the Treatment of Metastatic Melanoma.
    Trager MH; Geskin LJ; Saenger YM
    Curr Treat Options Oncol; 2020 Mar; 21(4):26. PubMed ID: 32266483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma.
    Seremet T; Planken S; Schwarze JK; Jansen Y; Vandeweerd L; van den Begin R; Tsechelidis I; Lienard D; Del Marmol V; Neyns B
    Melanoma Res; 2019 Feb; 29(1):85-88. PubMed ID: 30211812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
    Rothermel LD; Zager JS
    Expert Opin Biol Ther; 2018 Dec; 18(12):1199-1207. PubMed ID: 30392405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncolytic Virotherapy: A Contest between Apples and Oranges.
    Russell SJ; Peng KW
    Mol Ther; 2017 May; 25(5):1107-1116. PubMed ID: 28392162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanoma.
    Ahamadi M; Kast J; Chen PW; Huang X; Dutta S; Upreti VV
    CPT Pharmacometrics Syst Pharmacol; 2023 Feb; 12(2):250-260. PubMed ID: 36564918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma.
    Andtbacka RHI; Amatruda T; Nemunaitis J; Zager JS; Walker J; Chesney JA; Liu K; Hsu CP; Pickett CA; Mehnert JM
    EBioMedicine; 2019 Sep; 47():89-97. PubMed ID: 31409575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Talimogene Laherparepvec for the Treatment of Advanced Melanoma.
    Ott PA; Hodi FS
    Clin Cancer Res; 2016 Jul; 22(13):3127-31. PubMed ID: 27146699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report.
    Fröhlich A; Hoffmann F; Niebel D; Egger E; Kukuk GM; Toma M; Sirokay J; Bieber T; Landsberg J
    Front Oncol; 2020; 10():611. PubMed ID: 32457834
    [No Abstract]   [Full Text] [Related]  

  • 33. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Talimogene laherparepvec in the treatment of melanoma.
    Appleton ES; Turnbull S; Ralph C; West E; Scott K; Harrington K; Pandha H; Melcher A
    Expert Opin Biol Ther; 2015; 15(10):1517-30. PubMed ID: 26629575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.
    Eissa IR; Bustos-Villalobos I; Ichinose T; Matsumura S; Naoe Y; Miyajima N; Morimoto D; Mukoyama N; Zhiwen W; Tanaka M; Hasegawa H; Sumigama S; Aleksic B; Kodera Y; Kasuya H
    Cancers (Basel); 2018 Sep; 10(10):. PubMed ID: 30261620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
    Bommareddy PK; Aspromonte S; Zloza A; Rabkin SD; Kaufman HL
    Sci Transl Med; 2018 Dec; 10(471):. PubMed ID: 30541787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
    Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
    J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First Oncolytic Viral Therapy for Melanoma.
    Poh A
    Cancer Discov; 2016 Jan; 6(1):6. PubMed ID: 26552414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.
    Hamid O; Hoffner B; Gasal E; Hong J; Carvajal RD
    Cancer Immunol Immunother; 2017 Oct; 66(10):1249-1264. PubMed ID: 28712033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma.
    Hoffner B; Iodice GM; Gasal E
    Oncol Nurs Forum; 2016 Mar; 43(2):219-26. PubMed ID: 26906132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.